When the first COVID-19 vaccines were rolled out in late 2020, the world celebrated what was hailed as a triumph of science and human resilience. Yet, behind the headlines of success, there remains another story — one that is rarely spotlighted in official narratives, and one that many argue is just as important to tell.
The Race Against Time — and Transparency
Pharmaceutical giants such as Pfizer, Moderna, and AstraZeneca developed vaccines at unprecedented speed. While the rapid breakthrough was extraordinary, critics point out that the urgency left gaps in transparency.
Contracts between governments and pharmaceutical companies were often heavily redacted, shielding details about pricing, liability, and delivery schedules from the public.
In several countries, vaccine deals included indemnity clauses that protected manufacturers from lawsuits over potential side effects. This meant that governments — and ultimately taxpayers — shouldered the burden of compensation if adverse reactions occurred.
“That clause alone should have been a global conversation,” said a Lagos-based health policy analyst. “Instead, it was buried in technical documents that the public never saw.”
The Side Effects Debate
Millions safely received vaccines, but some reported adverse effects ranging from mild fever to more serious complications. Regulators like the U.S. CDC and Europe’s EMA acknowledged rare risks, such as blood clotting linked to the AstraZeneca vaccine or myocarditis in young men after mRNA shots.
However, victims and their families in many countries say they were ignored, stigmatized, or dismissed when they sought answers.
Compensation programs existed in theory but were bureaucratic and underfunded in practice. In Nigeria, where vaccine uptake was lower, skepticism spread rapidly through communities, often fueled by these unanswered questions.
The Profits of a Pandemic
COVID-19 vaccines generated record-breaking profits for pharmaceutical companies. Pfizer alone reported more than $37 billion in vaccine revenue in 2021, making it the best-selling pharmaceutical product in history.
Moderna, a company with no prior commercial product, suddenly became a global giant.
READ ALSO: Infertility Nightmare: The impact of COVID infection and vaccination
Critics argue that such profit-making, especially during a crisis, raised moral questions. “This was framed as humanity versus the virus, but it was also capitalism at its peak,” said an Abuja-based economist.
Many believe governments should have insisted on fairer pricing and knowledge-sharing, especially for poorer countries.
Africa’s Supply Struggles
Nowhere was inequality more visible than in Africa. While wealthy nations secured enough doses to vaccinate their populations several times over, African countries were left scrambling.
Nigeria, for instance, faced delayed shipments, expired doses, and logistical hurdles. COVAX, the global vaccine-sharing initiative, struggled to live up to its promise of equity.
This disparity fueled vaccine hesitancy, as many questioned why Africa always seemed to be last in line. “If the vaccines were truly about saving lives first, not profit, Africa wouldn’t have been left behind,” argued a public health activist in Kano.
The Silence Around Alternatives
Another part of the story seldom told is how alternative approaches were sidelined. Treatments and preventive measures, from repurposed drugs to local remedies, were often dismissed as “unscientific” even before large-scale studies were conducted.
For many communities, this reinforced the belief that the global system was designed to favor big pharmaceutical players rather than explore diverse solutions.
What the Future Holds
Five years on, COVID-19 remains a reminder of both scientific brilliance and systemic flaws. For some, the real “story they don’t want you to read” isn’t about hidden dangers or conspiracies — it’s about how power, profit, and politics shaped the biggest public health rollout in history.